This clinical trial is focused on studying a condition known as Chronic Myeloid Leukemia (CML). The trial involves patients who have previously attempted to stop their medication but needed to restart it. The medication being studied is called dasatinib, which is available in the form of film-coated tablets under the brand name SPRYCEL. The purpose of the study is to assess whether patients can maintain a state called major molecular remission, which means the disease is under control at a molecular level, after stopping the medication for a second time.

Participants in this study will have been treated with dasatinib for at least two years and must have shown a significant reduction in disease markers for at least one year. The study will observe patients over a period to see if they can maintain remission without the medication. The trial will also look at various factors that might influence the success of stopping the medication, such as biological markers and previous treatment history.

The study will monitor the proportion of patients who maintain remission at six and twelve months after stopping the medication again. It will also track any side effects that occur when the medication is stopped and any factors that might predict the success of stopping the medication. The trial aims to provide insights into the possibility of living without continuous medication for those with Chronic Myeloid Leukemia.